Pharma Legislation: From Pricing To Patents
Executive Summary
You may also be interested in...
End Of The 'March-In' Pricing Petitions?
KEI vows to continue battle over Bayh-Doyle restrictions after US Commerce Department suggests it may issue regulations to exclude pricing as a basis for requiring companies to license their patents.
Bill Requiring Justification For Rx Price Hikes Clears House Cmte.
House Ways & Means Committee clears legislation requiring manufacturers to justify 10% WAC increase in one year and 25% increase over three years, and to report number of free product samples.
CREATES Act Has a Penalty Problem
Republican House Energy and Commerce Committee members say potentially taking a company's revenue for blocking a generic company from obtaining samples, rather than profit, is excessive.